• Baxter International Inc., of Deerfield, Ill., said it started dosing patients with malignant solid tumors in a Phase I study of a fully human recombinant anti-macrophage migration inhibitory factor (MIF) monoclonal antibody. Read More
• Pfizer Inc., of New York, said the FDA approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML). The drug is intended for patients with chronic, accelerated or blast phase Philadelphia chromosome-positive CML who are resistant to or who cannot tolerate other therapies, including Gleevec (imatinib, Novartis AG). Read More
• Epizyme Inc., of Cambridge, Mass., said it initiated a Phase I study of EPZ-5676, a small-molecule inhibitor of histone methyltransferase DOT1L, to evaluate the drug's safety, pharmacokinetics and pharmacodynamics in escalating doses. Read More
• AMAG Pharmaceuticals Inc., of Lexington, Mass., received marketing authorization in Switzerland for Reinso (ferumoxytol) for iron deficiency anemia in adults with chronic kidney disease. Read More
F2G Ltd., of Manchester, UK, will use a new $30 million equity financing round to jump a lead candidate from its F3 series of preclinical compounds into first-in-man studies. Read More
While having, in effect, only one controlled trial to support approval of Novartis AG's TOBI Podhaler (TIP) raised flags for FDA reviewers, it didn't faze the agency's Anti-Infective Drugs Advisory Committee. Read More
